# Tasly Capital

Tasly Capital is a Private Equity based in Tianjin, China.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** Tianjin, China
- **Region:** Asia
- **Address:** Tianjin, China
- **Founded:** 2008
- **Assets under management:** Undisclosed
- **Website:** https://tasly.com
- **LinkedIn:** https://www.linkedin.com/company/taslycapital

## Regulatory record

- **Reports private funds:** No

## About

Tasly Capital is the investment arm of Tasly, a Chinese pharmaceutical company based in Tianjin. Tasly Capital has made 30 investments, including a Series B investment in Betterway Medical on March 16, 2026. The firm has 2 portfolio exits, with Hygieia Pharmaceuticals exiting on January 13, 2026.

## Sectors

- Healthcare Services
- Digital Health
- Enterprise Software

## Questions

### Is Tasly Capital a standalone fund manager or a corporate venture arm?

Tasly Capital operates as the corporate venture and private equity vehicle for Tasly Holding Group, a major Chinese pharmaceutical company. It deploys from the parent's corporate treasury and invests for strategic alignment alongside financial returns, rather than managing third-party LP capital in a traditional blind-pool structure. Its mandate is tied directly to Tasly Holding's commercial and R&D priorities.

### What investment stages does Tasly Capital target?

The firm spans early-stage venture through PIPE deals, with an emphasis on expansion and late-stage growth where commercial acceleration matters most. It writes checks to companies whose products or technologies can be scaled through the parent's manufacturing, distribution, and hospital network — a posture that favors assets approaching regulatory approval or market entry over pre-clinical science.

### Which sectors does Tasly Capital focus on?

Healthcare dominates: biotech, medical devices, diagnostics, and digital health platforms in particular. The firm also evaluates enterprise software serving clinical workflows and select consumer-health adjacencies that fit the parent's commercialization infrastructure. Pure-play tech or sectors outside healthcare get screened for whether Tasly Holding's physical and regulatory capabilities meaningfully advantage the portfolio company.

## Related profiles

- [TARO Ventures](https://altss.com/profile/taro-ventures)
- [Tavis Capital](https://altss.com/profile/tavis-capital)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/tasly-capital

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology